Alkem Laboratories Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Alkem Laboratories Ltd filed with BSE on 20 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Alkem Laboratories reported Q1 FY27 revenue of INR3,740 crores, up close to 11% year-on-year, with India sales of INR2,497 crores growing 10.3% and international sales of INR1,222 crores growing 16%. EBITDA margin was 20.5%, up 3.7% year-on-year, while net profit declined 21.7% due to taxation reasons. Management discussed slower growth in the Trade Generics business, cost impacts from new hiring and the Enzene CDMO business, an OAI status at the Daman facility, and delays in the Occlutech integration and denosumab biosimilar approval.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue from operations: INR3,740 crores (Q1 FY27)
p. 3
“the key highlights are that our revenue from operation was INR3,740 crores with a year-on-year growth of close to 11%.”
Sandeep Singh, page 3 of the filed PDF · View the filing
India sales: INR2,497 crores (Q1 FY27)
p. 3
“India sales were INR2,497 crores and year-on-year growth was 10.3%.”
Sandeep Singh, page 3 of the filed PDF · View the filing
International sales: INR1,222 crores (Q1 FY27)
p. 4
“International sales was INR1,222 crores with year-on-year growth of 16%.”
Sandeep Singh, page 4 of the filed PDF · View the filing
EBITDA margin: 20.5% (Q1 FY27)
p. 4
“EBITDA margin was 20.5%.”
Sandeep Singh, page 4 of the filed PDF · View the filing
R&D expenses as % of revenue: 4% (Q1 FY27)
p. 4
“R&D expenses was 4% of our total revenue.”
Sandeep Singh, page 4 of the filed PDF · View the filing
Net profit growth: -21.7% (Q1 FY27)
p. 4
“the net profit, there was a degrowth of 21.7%.”
Sandeep Singh, page 4 of the filed PDF · View the filing
Company growth vs IPM: 13.2% vs 12.2% (Q1 FY27)
p. 4
“the company registered a growth of 13.2% year-on-year versus the Indian pharmaceutical market, which grew by 12.2%.”
Sandeep Singh, page 4 of the filed PDF · View the filing
Acute segment growth vs IPM: 12.3% vs 10.1% (Q1 FY27)
p. 4
“Acute segment reported a growth of 12.3% versus the IPM, which grew by 10.1%, which is a 220 basis point outperformance.”
Sandeep Singh, page 4 of the filed PDF · View the filing
Chronic segment growth vs IPM: 17.9% vs 15.4% (Q1 FY27)
p. 4
“Chronic segment reported a growth of 17.9% versus the IPM, which grew by 15.4%, 250 basis point outperformance.”
Sandeep Singh, page 4 of the filed PDF · View the filing
ANDA approvals: 5 ANDAs (Q1 FY27)
p. 4
“During the quarter, for the U.S. market, the company received 5 ANDAs approval.”
Sandeep Singh, page 4 of the filed PDF · View the filing
Branded generics growth: 12% (Q1 FY27)
p. 4
“It was 12%.”
Sandeep Singh, page 4 of the filed PDF · View the filing
Employee cost growth: more than 16% (Q1 FY27)
p. 5
“in terms of employee cost, yes, the growth is more than 16% in the quarter.”
Nitin Agrawal, page 5 of the filed PDF · View the filing
Occlutech/Ortho EBITDA loss: INR5 crores to INR7 crores (Q1 FY27)
p. 5
“there was an EBITDA loss of around INR5 crores to INR7 crores because we are also investing into this business.”
Nitin Agrawal, page 5 of the filed PDF · View the filing
U.S. CDMO operational expense: INR60 crores (Q1 FY27)
p. 5
“U.S. we incur around INR60 crores of operational expense.”
Nitin Agrawal, page 5 of the filed PDF · View the filing
India biosimilar annual sales: INR150 crores
p. 6
“we do around INR150 crores of annual sales.”
Nitin Agrawal, page 6 of the filed PDF · View the filing
Revenue from Daman facility as % of U.S. revenue: 45%
p. 7
“I think 45% of our U.S. revenue comes from this facility.”
Sandeep Singh, page 7 of the filed PDF · View the filing
India price/volume/new launches growth: Price 6%, new launches 3%, volume 2% (Q1 FY27)
p. 11
“in terms of price, the growth was around 6%.”
Nitin Agrawal, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Occlutech sales target — INR400 crores of sales with breakeven EBITDA · this year (8.5 months)
stated firmly by Nitin Agrawal
p. 6
“this year for around 8.5 months, our target for Occlutech is around INR400 crores of sales with breakeven EBITDA because of delays happened in case of integration.”
Nitin Agrawal, page 6 of the filed PDF · View the filing
Occlutech EBITDA margin improvement — 7% to 8% improvement in EBITDA year-on-year · 3 to 4 years
stated as an aspiration by Nitin Agrawal
p. 7
“you can see a 7% to 8% improvement in EBITDA year-on-year and we target to achieve our guidance over 3 to 4 years.”
Nitin Agrawal, page 7 of the filed PDF · View the filing
U.S. CDMO breakeven — USD25 million to USD30 million annualized revenue · beyond next 12 months
stated conditionally by Sandeep Singh
p. 8
“The revenues what we need perhaps will be close to USD20 million to breakeven.”
Sandeep Singh, page 8 of the filed PDF · View the filing
Consolidated tax rate — 30% to 32% · FY27
stated firmly by Nitin Agrawal
p. 10
“at consolidated level, it will be in the range of around 30% to 32% because a few of the entities like our Enzene in U.S. and all, which are reporting losses”
Nitin Agrawal, page 10 of the filed PDF · View the filing
U.S. sales growth — mid to high single digit · FY27
stated conditionally by Sandeep Singh
p. 12
“I think it will be high single digit to mid.”
Sandeep Singh, page 12 of the filed PDF · View the filing
Gross margin guidance — 66.5% to 67% · balance part of the year
stated conditionally by Nitin Agrawal
p. 13
“we maintain the same guidance of 66.5% to 67% of gross margins for balance part of the year.”
Nitin Agrawal, page 13 of the filed PDF · View the filing
India combined business growth — close to 12% · FY27
stated conditionally by Sandeep Singh
p. 12
“Yes, we could end up by close to 12%, yes.”
Sandeep Singh, page 12 of the filed PDF · View the filing
Trade Generics growth recovery — late single digits · next 1 to 2 years
stated as an aspiration by Sandeep Singh
p. 10
“personally, as a promoter MD, I'll be happy with late single digits is perfectly all right.”
Sandeep Singh, page 10 of the filed PDF · View the filing
Daman OAI resolution — 6 to 12 months
stated as an aspiration by Sandeep Singh
p. 12
“we believe that we'll come out of this in 6 to 12 months' time, hopefully.”
Sandeep Singh, page 12 of the filed PDF · View the filing
U.S. CDMO breakeven timeline — next 12 months
stated firmly by Sandeep Singh
p. 8
“next 12 months will not breakeven, just to be very clear.”
Sandeep Singh, page 8 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management attributed the drag to weak Trade Generics growth, which now contributes meaningfully to domestic formulations.
Answered by Sandeep Singh
Asked by Saion Mukherjee: Why is India growth lower than peers despite outperforming IQVIA market growth?
p. 4
“I think the India growth rate is kind of dragged down because of the Trade Generics.”
Sandeep Singh, page 4 of the filed PDF · View the filing
CFO detailed employee cost growth from increments, MR additions, Enzene CDMO, and currency impact on other expenses.
Answered by Nitin Agrawal
Asked by Saion Mukherjee: How much of the cost increase is from CDMO/MedTech businesses?
p. 5
“the CDMO business in Enzene became operational from November '25.”
Nitin Agrawal, page 5 of the filed PDF · View the filing
Approval has been delayed beyond the goal date by a few months.
Answered by Sandeep Singh
Asked by Sandeep Kumar: What is the status of denosumab biosimilar approval in the U.S.?
p. 5
“denosumab biosimilar approval is a little bit off. So we did not get the approval on the goal date.”
Sandeep Singh, page 5 of the filed PDF · View the filing
Launch expected in approximately three months.
Answered by Sandeep Singh
Asked by Sandeep Kumar: When will Xgeva biosimilar launch in Europe?
p. 6
“We could be like 3 months away.”
Sandeep Singh, page 6 of the filed PDF · View the filing
The company has launched 7 biosimilars generating around INR150 crores in annual sales with improved margins from backward integration.
Answered by Nitin Agrawal
Asked by Amlan Jyoti Das: How has the India biosimilar portfolio performed since launch?
p. 6
“we have already launched 7 products, as you said, and we do around INR150 crores of annual sales.”
Nitin Agrawal, page 6 of the filed PDF · View the filing
Management expects gradual margin improvement over 3-4 years after a delayed start.
Answered by Nitin Agrawal
Asked by Amlan Jyoti Das: How will Occlutech margins evolve given the delayed integration?
p. 7
“you can see a 7% to 8% improvement in EBITDA year-on-year and we target to achieve our guidance over 3 to 4 years.”
Nitin Agrawal, page 7 of the filed PDF · View the filing
Management indicated an annualized revenue target of USD25-30 million, with breakeven not expected within the next 12 months.
Answered by Sandeep Singh
Asked by Kunal Dhamesha: What revenue is needed for U.S. CDMO to break even?
p. 8
“USD25 million to USD30 million, we'll break even over there.”
Sandeep Singh, page 8 of the filed PDF · View the filing
Management cited increased competition and internal tightening of receivable/DSO practices as reasons for slower growth.
Answered by Sandeep Singh
Asked by Kunal Dhamesha: Why is the Trade Generics business not growing?
p. 7
“It has got very intensive, the competition.”
Sandeep Singh, page 7 of the filed PDF · View the filing
Management set a modest expectation for late single-digit growth in Trade Generics and confirmed an ongoing CEO search.
Answered by Sandeep Singh
Asked by Abdulkader Puranwala: When will Trade Generics growth recover, and are there CEO hiring updates?
p. 10
“we told you last time, we are looking out. So thoughts are the same.”
Sandeep Singh, page 10 of the filed PDF · View the filing
Management said price erosion has bottomed out and volume growth is limited, with currency helping, guiding to mid-to-high single digit growth for the year.
Answered by Sandeep Singh
Asked by Rashmi Shetty: What explains softness in U.S. sales and what is the updated full-year outlook?
p. 12
“U.S. is challenging. We really don't have volume growth. It's more because of currency, and that remains a reality in these products.”
Sandeep Singh, page 12 of the filed PDF · View the filing
Management said the international growth is sustainable, with smaller markets like Germany growing fast off a low base; gross margin improvement was due to product mix and currency support.
Answered by Sandeep Singh
Asked by Amlan Jyoti Das: How sustainable is international business double-digit growth, and what drove gross margin improvement?
p. 13
“this is quite sustainable, more than sustainable. Yes, we are seeing good double-digit growth.”
Sandeep Singh, page 13 of the filed PDF · View the filing
Risks flagged
Daman facility received OAI status from the regulator
p. 4
“Recently, our Daman facility has received an OAI status.”
Sandeep Singh, page 4 of the filed PDF · View the filing
Delayed denosumab biosimilar approval in the U.S.
p. 5
“denosumab biosimilar approval is a little bit off. So we did not get the approval on the goal date. So that is pushed off by at least a few months.”
Sandeep Singh, page 5 of the filed PDF · View the filing
Intensified competition in Trade Generics segment
p. 7
“4, 5 years back, you will remember that not many companies wanted to play in this segment, but now a lot of big guys have entered.”
Sandeep Singh, page 7 of the filed PDF · View the filing
U.S. CDMO business will not break even within the next 12 months
p. 8
“next 12 months will not breakeven, just to be very clear.”
Sandeep Singh, page 8 of the filed PDF · View the filing
Lack of volume growth in U.S. business, reliant on currency
p. 12
“We really don't have volume growth. It's more because of currency, and that remains a reality in these products.”
Sandeep Singh, page 12 of the filed PDF · View the filing
API price increases expected to affect gross margins in subsequent quarters
p. 13
“in subsequent quarters, there will be impact because of API prices.”
Nitin Agrawal, page 13 of the filed PDF · View the filing
Occlutech integration delayed, affecting sales and margin targets
p. 6
“the original plan was to complete the acquisition and start integration sometime in first quarter, but that got delayed.”
Nitin Agrawal, page 6 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.